Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care

Long-acting injectables (LAIs) offer an opportunity to improve adherence and potential outcomes for patients with schizophrenia LongActingImpact.com is a new resource center designed to support clinicians in having informed treatment conversations with those living with schizophrenia As a leader in neuroscience, Teva is committed to supporting clinicians by providing evidence-based resources which could help improve […]